Methods for treating or preventing ophthalmological conditions
The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.
1. A method of treating geographic atrophy (GA) in a human subject in need thereof, the method comprising administering to the eye of said subject from about 0.3 mg/eye to about 5 mg/eye of a pegylated aptamer;
wherein the aptamer comprises the sequence
(SEQ ID NO: 26)
fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmG
mAmGfUfUfUAfCfCfUmGfCmG--3T,
wherein fC and fU=2′-fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine, or a salt thereof;
wherein administration of the pegylated aptamer reduces growth of a lesion associated with geographic atrophy in the subject; and
wherein the pegylated aptamer is administered to the subject biweekly, monthly, or quarterly; and wherein the pegylated aptamer is an anti-C5 agent.
2. The method according to claim 1 , wherein the pegylated aptamer is provided as a pegylated moiety conjugated to the aptamer via a linker.
3. The method according to claim 2 , wherein the pegylated moiety is conjugated to the 5′ end of the aptamer.
4. The method according to claim 2 , wherein the pegylated moiety is a branched PEG.
5. The method according to claim 2 , wherein the pegylated moiety has a molecular weight greater than about 10 kDA.
6. The method according to claim 2 , wherein the pegylated moiety has a molecular weight of about 40 kDa.
7. The method according to claim 1 , wherein the pegylated moiety has the following structure:
8. The method according to claim 1 , wherein administration of the agent reduces a lesion associated with geographic atrophy in the subject.
9. The method according to claim 8 , wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 10% as compared to a subject who is not administered the anti-C5 agent.
10. The method according to claim 1 , wherein the anti-C5 agent is administered monthly.
11. The method according to claim 10 , wherein the anti-C5 agent is administered monthly for three injections, and the fourth and fifth injections are administered three or four months after the third injection.
12. The method according to claim 1 , wherein the anti-C5 agent is administered bimonthly.
13. The method according to claim 1 , wherein the anti-C5 agent is administered quarterly.
14. The method according to claim 1 , wherein about 0.5 mg to about 2 mg/eye of a pegylated aptamer is administered to the subject.
15. The method according to claim 1 , wherein about 1 mg/eye of a pegylated aptamer is administered to the subject.
16. The method according to claim 1 , wherein the pegylated aptamer is provided as a granulate, suspension, emulsion, solution, gel, hydrogel, paste, ointment, cream, plaster, delivery device, injectable, implant, intraocular implant, spray, drop or aerosol.
17. The method according to claim 1 , wherein administration is intravitreal or periocular.
18. The method according to claim 1 , wherein administration is to the anterior or posterior chamber of the subject's eye.
19. The method according to claim 1 , wherein the pegylated aptamer is provided as a controlled release formulation.